Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1432 of 5804
-
Stroke recovery revolution: your daily moves could shape your rehab
Knowledge-focused CompletedGoal of research program: To understand person-specific factors, such as imaging markers and activity patterns early after stroke, that may guide precision rehabilitation to optimize function and improve recovery. Objectives: 1. Test the effect of reducing sedentary behaviour e…
Phase: NA • Sponsor: University of Alberta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
New program aims to curb youth violence by addressing racism and sexism
Prevention OngoingThis cluster-randomized community-partnered study will examine the effectiveness of a racial-, gender-, and economic-justice focused youth violence prevention program called Forging Hopeful Futures with youth ages 13-19.
Phase: NA • Sponsor: University of Pittsburgh • Aim: Prevention
Last updated Jun 27, 2026 07:56 UTC
-
Could an immune treatment ease long COVID brain fog?
Symptom relief ENROLLING_BY_INVITATIONBackground: COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way. Researchers want to see if a treatment can help with people who have recovered from COVID-19 but still have …
Phase: PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
MRI-Guided brain zaps aim to ease depression
Symptom relief CompletedThe study will compare the efficacy of intermittent Theta Burst Stimulation (iTBS) with DLPFC-pgACC personalized target for major depressive disorder (MDD) and explore possible brain network mechanisms. The stimulated targets will be located by magnetic resonance imaging (MRI) ba…
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Can a Home-Based virtual program help cancer survivors regain their lives?
Symptom relief Recruiting nowPragmatic hybrid type 1 effectiveness-implementation (E-I) trial of a virtual cancer rehabilitation program: The study team will conduct a multi-center hybrid type I effectiveness-implementation study to examine the clinical effectiveness and implementation potential of an 8-week…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Cancer drug could help patients with low platelet disorder
Disease control Recruiting nowto investigate efficacy and safety evaluation of bortezomib in patients with relapsed/refractory immune thrombocytopenia
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a diabetes drug curb alcohol cravings? new study says maybe.
Disease control CompletedThe purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
Phase: PHASE2 • Sponsor: Oklahoma State University Center for Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Could a new drug free kidney transplant patients from lifelong pills?
Disease control OngoingThis study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, DR) HLA mismatched unrelated li…
Phase: PHASE1 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New HIV study offers patients a choice: daily pill or bimonthly shot
Disease control CompletedThis is a multicentre study carried out in participants living with human immunodeficiency virus type 1 (HIV-1) who have not previously been treated with any antiretroviral therapies. The study will investigate two 2-drug regimens for the treatment of HIV-1: a fixed-dose combinat…
Phase: PHASE3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can an arthritis drug speed COVID-19 recovery? new trial tests abatacept
Disease control CompletedCOVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while pa…
Phase: PHASE4 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 26, 2026 14:07 UTC
-
Old antibiotic, new hope: novobiocin targets Cancer's weak DNA repair
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repa…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New allergy shot shows promise for those failed by standard meds
Symptom relief CompletedAllergic rhinitis (AR) affects large population worldwide, the most commonly used medication include anti-histamine, nasal spray and anti-LTRAs inhibitors (leukotriene receptor antagonists), Even after those first-line treatment, there is still a large number of patient (\~20%) a…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New hope for PNH patients in china: eculizumab shows promise
Disease control CompletedThis is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in adult participants with paraxysmal noturnal hemoglobinuria (PNH) in China.
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a plant extract make rectal cancer treatment easier to tolerate?
Symptom relief OngoingThe goal of this clinical trial is to see, if addition of chlorophyllin to neoadjuvant Chemo-radiotherapy can reduce the gastro-intestinal/genitourinary/hematological toxicity rates and improve the quality of life in patient's diagnosed with locally advanced rectal cancer. This …
Phase: PHASE2 • Sponsor: Tata Memorial Centre • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can a Two-Drug cocktail reverse liver scarring? early trial hints at possibility
Disease control CompletedTo examine the effect of dasatinib plus quercetin on liver fibrosis in individuals with biopsy proven NAFLD with fibrosis by performing a double-blind randomized controlled proof-of-principle study
Phase: PHASE1, PHASE2 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New targeted drug shows promise for rare bile duct cancer
Disease control Recruiting nowThis is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Phase: PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill could tame rare hormone disorder
Disease control CompletedThe purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for kids with rare nerve disease: drug trial launches
Disease control Recruiting nowA Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to \< 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive fo…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
5-year follow-up checks if imlifidase helps kidney transplants last longer
Disease control OngoingA prospective, post-authorisation long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation, including a non-comparative concurrent reference cohort.
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New anxiety drug shows promise in early trial
Symptom relief CompletedThe ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Phase: PHASE2 • Sponsor: Engrail Therapeutics INC • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC